Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Brain Cancer-Pipeline Review, H1 2015

Brain Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Brain Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Brain Cancer-Pipeline Review, H1 2015', provides an overview of the Brain Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Brain Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Brain Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Brain Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Brain Cancer-Overview 10

Pipeline Products for Brain Cancer-Comparative Analysis 11

Brain Cancer-Therapeutics under Development by Companies 12

Brain Cancer-Therapeutics under Investigation by Universities/Institutes 16

Brain Cancer-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Brain Cancer-Products under Development by Companies 20

Brain Cancer-Products under Investigation by Universities/Institutes 24

Brain Cancer-Companies Involved in Therapeutics Development 25

AbbVie Inc. 25

AngioChem Inc. 26

Arrien Pharmaceuticals, LLC 27

BBB Therapeutics B.V. 28

biOasis Technologies Inc. 29

Bionomics Limited 30

Bristol-Myers Squibb Company 31

Cavion LLC 32

Critical Outcome Technologies Inc. 33

CureFAKtor Pharmaceuticals, LLC 34

Diffusion Pharmaceuticals LLC 35

e-Therapeutics plc 36

Eisai Co., Ltd. 37

Exelixis, Inc. 38

GlaxoSmithKline plc 39

Hutchison MediPharma Limited 40

Merrimack Pharmaceuticals, Inc. 41

Nanobiotix 42

Nektar Therapeutics 43

Nerviano Medical Sciences S.r.l. 44

Neuralstem, Inc. 45

Novartis AG 46

Oncology Research International Limited 47

Pfizer Inc. 48

Philogen S.p.A. 49

Phosplatin Therapeutics 50

Prana Biotechnology Limited 51

Puma Biotechnology, Inc. 52

RadioRx, Inc. 53

Sagetis Biotech, S.L. 54

Sanofi 55

Spectrum Pharmaceuticals, Inc. 56

Stemline Therapeutics, Inc. 57

Takeda Pharmaceutical Company Limited 58

ThromboGenics NV 59

Tocagen Inc. 60

Zymeworks Inc. 61

Brain Cancer-Therapeutics Assessment 62

Assessment by Monotherapy Products 62

Assessment by Combination Products 63

Assessment by Target 64

Assessment by Mechanism of Action 67

Assessment by Route of Administration 70

Assessment by Molecule Type 72

Drug Profiles 74

(dabrafenib mesylate + trametinib dimethyl sulfoxide)-Drug Profile 74

2B3-101-Drug Profile 76

ANG-1005-Drug Profile 78

ANG-4043-Drug Profile 80

ARN-7016-Drug Profile 81

BNC-105-Drug Profile 82

BT-2111-Drug Profile 83

cabazitaxel-Drug Profile 84

cabozantinib s-malate-Drug Profile 86

CFAKC-4-Drug Profile 89

COTI-2-Drug Profile 90

dabrafenib mesylate-Drug Profile 93

dacomitinib-Drug Profile 96

dexanabinol-Drug Profile 98

Drug for Brain Metastasis-Drug Profile 100

erismodegib-Drug Profile 101

etirinotecan pegol-Drug Profile 104

Gene Therapy for Brain Cancer-Drug Profile 107

Gene Therapy to Activate p53 for Oncology-Drug Profile 108

HMPL-813-Drug Profile 109

ipilimumab-Drug Profile 110

irinotecan sucrosofate liposomal-Drug Profile 113

KML-001-Drug Profile 116

lapatinib ditosylate-Drug Profile 118

LEQ-506-Drug Profile 122

lucanthone hydrochloride-Drug Profile 123

MDNA-55-Drug Profile 125

mibefradil dihydrochloride-Drug Profile 126

Monoclonal Antibody for Brain Cancer and Metastatic Breast Cancer-Drug Profile 128

NBTX-IV-Drug Profile 129

neratinib-Drug Profile 130

nimotuzumab-Drug Profile 134

NMSE-973-Drug Profile 137

NSI-566-Drug Profile 138

ORIL-007-Drug Profile 140

PB-357-Drug Profile 141

PBT-519-Drug Profile 142

pritumumab-Drug Profile 143

PT-112-Drug Profile 145

RAD-1901-Drug Profile 146

radretumab-Drug Profile 148

RRX-001-Drug Profile 150

SAG-002-Drug Profile 151

SAG-003-Drug Profile 152

siomycin A-Drug Profile 153

SL-301-Drug Profile 154

SL-302-Drug Profile 155

Small Molecule for Brain Cancer-Drug Profile 156

Small Molecule for Brain Cancer and Malignant Glioma-Drug Profile 157

Small Molecule for Oncology-Drug Profile 158

Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma-Drug Profile 159

TB-403-Drug Profile 160

TBX-02-Drug Profile 162

TPI-287-Drug Profile 163

transcrocetinate sodium-Drug Profile 165

TTL-1177-Drug Profile 166

ubidecarenone-Drug Profile 167

Vaccine for Glioblastoma Multiforme-Drug Profile 169

veliparib-Drug Profile 170

vocimagene amiretrorepvec + flucytosine ER-Drug Profile 173

Brain Cancer-Recent Pipeline Updates 175

Brain Cancer-Dormant Projects 244

Brain Cancer-Discontinued Products 248

Brain Cancer-Product Development Milestones 249

Featured News & Press Releases 249

Appendix 258

Methodology 258

Coverage 258

Secondary Research 258

Primary Research 258

Expert Panel Validation 258

Contact Us 259

Disclaimer 259

List of Tables

Number of Products under Development for Brain Cancer, H1 2015 14

Number of Products under Development for Brain Cancer-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Development, H1 2015 23

Products under Development by Companies, H1 2015 24

Products under Development by Companies, H1 2015 (Contd..1) 25

Products under Development by Companies, H1 2015 (Contd..2) 26

Products under Development by Companies, H1 2015 (Contd..3) 27

Products under Investigation by Universities/Institutes, H1 2015 28

Brain Cancer-Pipeline by AbbVie Inc., H1 2015 29

Brain Cancer-Pipeline by AngioChem Inc., H1 2015 30

Brain Cancer-Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 31

Brain Cancer-Pipeline by BBB Therapeutics B.V., H1 2015 32

Brain Cancer-Pipeline by biOasis Technologies Inc., H1 2015 33

Brain Cancer-Pipeline by Bionomics Limited, H1 2015 34

Brain Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 35

Brain Cancer-Pipeline by Cavion LLC, H1 2015 36

Brain Cancer-Pipeline by Critical Outcome Technologies Inc., H1 2015 37

Brain Cancer-Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 38

Brain Cancer-Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 39

Brain Cancer-Pipeline by e-Therapeutics plc, H1 2015 40

Brain Cancer-Pipeline by Eisai Co., Ltd., H1 2015 41

Brain Cancer-Pipeline by Exelixis, Inc., H1 2015 42

Brain Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 43

Brain Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 44

Brain Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 45

Brain Cancer-Pipeline by Nanobiotix, H1 2015 46

Brain Cancer-Pipeline by Nektar Therapeutics, H1 2015 47

Brain Cancer-Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 48

Brain Cancer-Pipeline by Neuralstem, Inc., H1 2015 49

Brain Cancer-Pipeline by Novartis AG, H1 2015 50

Brain Cancer-Pipeline by Oncology Research International Limited, H1 2015 51

Brain Cancer-Pipeline by Pfizer Inc., H1 2015 52

Brain Cancer-Pipeline by Philogen S.p.A., H1 2015 53

Brain Cancer-Pipeline by Phosplatin Therapeutics, H1 2015 54

Brain Cancer-Pipeline by Prana Biotechnology Limited, H1 2015 55

Brain Cancer-Pipeline by Puma Biotechnology, Inc., H1 2015 56

Brain Cancer-Pipeline by RadioRx, Inc., H1 2015 57

Brain Cancer-Pipeline by Sagetis Biotech, S.L., H1 2015 58

Brain Cancer-Pipeline by Sanofi, H1 2015 59

Brain Cancer-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 60

Brain Cancer-Pipeline by Stemline Therapeutics, Inc., H1 2015 61

Brain Cancer-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 62

Brain Cancer-Pipeline by ThromboGenics NV, H1 2015 63

Brain Cancer-Pipeline by Tocagen Inc., H1 2015 64

Brain Cancer-Pipeline by Zymeworks Inc., H1 2015 65

Assessment by Monotherapy Products, H1 2015 66

Assessment by Combination Products, H1 2015 67

Number of Products by Stage and Target, H1 2015 69

Number of Products by Stage and Mechanism of Action, H1 2015 72

Number of Products by Stage and Route of Administration, H1 2015 75

Number of Products by Stage and Molecule Type, H1 2015 77

Brain Cancer Therapeutics-Recent Pipeline Updates, H1 2015 179

Brain Cancer-Dormant Projects, H1 2015 248

Brain Cancer-Dormant Projects (Contd..1), H1 2015 249

Brain Cancer-Dormant Projects (Contd..2), H1 2015 250

Brain Cancer-Dormant Projects (Contd..3), H1 2015 251

Brain Cancer-Discontinued Products, H1 2015 252

List of Figures

Number of Products under Development for Brain Cancer, H1 2015 14

Number of Products under Development for Brain Cancer-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Products, H1 2015 23

Assessment by Monotherapy Products, H1 2015 66

Assessment by Combination Products, H1 2015 67

Number of Products by Top 10 Targets, H1 2015 68

Number of Products by Stage and Top 10 Targets, H1 2015 68

Number of Products by Top 10 Mechanism of Actions, H1 2015 71

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 71

Number of Products by Top 10 Routes of Administration, H1 2015 74

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 75

Number of Products by Top 10 Molecule Types, H1 2015 76

Number of Products by Stage and Top 10 Molecule Types, H1 2015 77

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

AngioChem Inc.

Arrien Pharmaceuticals, LLC

BBB Therapeutics B.V.

biOasis Technologies Inc.

Bionomics Limited

Bristol-Myers Squibb Company

Cavion LLC

Critical Outcome Technologies Inc.

CureFAKtor Pharmaceuticals, LLC

Diffusion Pharmaceuticals LLC

e-Therapeutics plc

Eisai Co., Ltd.

Exelixis, Inc.

GlaxoSmithKline plc

Hutchison MediPharma Limited

Merrimack Pharmaceuticals, Inc.

Nanobiotix

Nektar Therapeutics

Nerviano Medical Sciences S.r.l.

Neuralstem, Inc.

Novartis AG

Oncology Research International Limited

Pfizer Inc.

Philogen S.p.A.

Phosplatin Therapeutics

Prana Biotechnology Limited

Puma Biotechnology, Inc.

RadioRx, Inc.

Sagetis Biotech, S.L.

Sanofi

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

ThromboGenics NV

Tocagen Inc.

Zymeworks Inc.

Brain Cancer Therapeutic Products under Development, Key Players in Brain Cancer Therapeutics, Brain Cancer Pipeline Overview, Brain Cancer Pipeline, Brain Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com